Muhammad Arham | AI in Drug Discovery | Innovative Research Award

Innovative Research Award

Muhammad Arham
The University of Faisalabad, Pakistan

Muhammad Arham
Affiliation The University of Faisalabad
Country Pakistan
Google Scholar tRiYSVcAAAAJ&hl
Documents 6
Citations 5
h-index 2
Subject Area AI in Drug Discovery
Event Computational Biologists Awards
ORCID 0009-0008-8496-9615

Muhammad Arham is a researcher affiliated with The University of Faisalabad whose recorded research profile is associated with artificial intelligence applications in drug discovery. Available bibliographic information identifies a Scopus author record containing two documents, two citations, and an h-index of 1. These indicators provide a limited quantitative snapshot of scholarly activity and should be interpreted in relation to publication age, field norms, and research development. [1]

Abstract

Muhammad Arham is affiliated with The University of Faisalabad, Pakistan, and has a documented research profile connected with artificial intelligence in drug discovery. His indexed record currently reports two documents, two citations, and an h-index of 1. The research area represents an interdisciplinary intersection of computational biology, artificial intelligence, pharmaceutical science, and data-driven discovery. Such approaches can support the analysis of biological and chemical information, prioritization of candidate compounds, prediction of molecular properties, and development of computational workflows for drug research. The present profile summarizes available scholarly indicators and assesses relevance to an Innovative Research Award within computational biology. [1]

Keywords

Artificial intelligence; drug discovery; computational biology; bioinformatics; machine learning; pharmaceutical research; molecular modeling; computational drug design. These keywords describe the interdisciplinary context in which artificial intelligence methods may be applied to biological and pharmaceutical research problems.

Introduction

Artificial intelligence has become an important computational approach in modern drug discovery, where large biological, chemical, and clinical datasets can be analyzed using machine learning and related computational techniques. AI-assisted workflows may contribute to target identification, compound screening, molecular property prediction, and optimization of candidate molecules. [2] Within computational biology, these methods provide a bridge between biological data interpretation and predictive computational modeling.

Research Profile

The available profile places Muhammad Arham within an interdisciplinary research environment at The University of Faisalabad, with AI in Drug Discovery identified as the principal subject area. The Scopus record associated with author ID 60694808200 contains two indexed documents and two citations, with an h-index of 1. These records establish an emerging scholarly profile, although bibliometric indicators alone cannot fully characterize methodological quality or scientific contribution. [1]

Research Contributions

Research at the intersection of artificial intelligence and drug discovery can contribute computational methods for handling complex molecular and biological datasets. Relevant approaches include machine learning models, predictive analytics, molecular representation, virtual screening, and computational prioritization of drug candidates. [2] The documented subject area therefore aligns with a broader research direction in which computational techniques are used to support pharmaceutical discovery and biological interpretation.

Publications

The available Scopus record reports two documents associated with the researcher. Because the supplied information does not provide publication titles, journals, publication years, authorship positions, or article-level DOI information, no additional publication details are inferred here. The reported document count should therefore be regarded as the bibliographic information available for this profile at the time of assessment. [1]

Research Impact

The recorded profile currently has two citations and an h-index of 1. These indicators suggest measurable but early-stage bibliometric visibility. Citation counts and h-index values can vary substantially according to discipline, publication age, database coverage, and citation practices, so they are best considered alongside qualitative evidence such as methodological originality, reproducibility, collaboration, and practical relevance. [1]

Award Suitability

The research area identified for Muhammad Arham is relevant to an Innovative Research Award because AI-driven drug discovery is a developing interdisciplinary field with applications across computational biology and pharmaceutical research. The available evidence establishes subject-area relevance and a documented scholarly record, while the limited bibliometric volume indicates that award evaluation should also consider the specific novelty, technical rigor, validation, and potential significance of the underlying research contributions. [2] Final award determination should therefore be based on the complete nomination dossier and independent assessment criteria.

Conclusion

Muhammad Arham’s documented academic profile reflects an emerging research trajectory associated with AI in Drug Discovery at The University of Faisalabad. The available bibliometric record includes two documents, two citations, and an h-index of 1. While these metrics provide a concise indication of indexed scholarly activity, they do not independently establish research quality or innovation. The profile is nevertheless thematically aligned with computational approaches to contemporary drug discovery and may be considered within an award assessment framework that evaluates substantive scientific contribution. [1]

References

  1. Journal article. (2026). Harnessing Deep Learning Models for Guide RNA Optimization and Off-Target Prediction in CRISPR Systems.
    https://doi.org/10.1002/biot.70255
  2. Google Scholar. (n.d.). Rahim Zahedi, Author ID tRiYSVcAAAAJ&hl. Google Scholar author profile.
    https://scholar.google.com/citations?user=tRiYSVcAAAAJ&hl=en
  3. Journal article. (2026). Next-Generation Artificial Intelligence Strategies for Mechanistic Cancer Target Discovery and Drug Development: A State-of-the-Art Review.
    https://doi.org/10.1016/j.drudis.2018.11.014
  4. ORCID. (n.d.). ORCID record: Muhammad Arham. ORCID.
    https://orcid.org/0009-0008-8496-9615
  5. Computational Biologists Awards. (2026.). Official award website.
    https://computationalbiologists.com/

Eyachew Misganew Tegaw | AI in Personalized Medicine | Best Researcher Award

Assist. Prof. Dr. Eyachew Misganew Tegaw | AI in Personalized Medicine | Best Researcher Award

Assistant Professor of Medical Physics at  Debre Tabor University, Ethiopia.

Dr. Eyachew Misganew Tegaw is an Assistant Professor of Medical Physics at Debre Tabor University, Ethiopia. He earned his Ph.D. from Tehran University of Medical Sciences, specializing in intraoperative radiotherapy using nanoparticles for breast cancer treatment. His research spans medical imaging, radiation therapy, nanomedicine, and AI applications in oncology. Dr. Eyachew Misganew Tegaw has published extensively in peer-reviewed journals and actively contributes to scientific advancement through research, mentorship, and international collaboration.

👨‍🎓 Educational Background:

Eyachew Misganew Tegaw holds a Ph.D. in Medical Physics from the Tehran University of Medical Sciences (TUMS), Iran, where he specialized in intraoperative radiotherapy (IORT) using nanoparticles for breast cancer treatment. His academic journey began with a B.Sc. in Applied Physics from the University of Gondar, followed by an M.Sc. in Condensed Matter Physics from Mekelle University. Across these programs, he built a strong foundation in quantum mechanics, computational physics, and radiation therapy physics, gaining multidisciplinary expertise in both theoretical and applied domains.

Profile:

👨‍🏫 Professional Experience:

With over a decade of academic service, Dr. Eyachew Misganew Tegaw currently serves as an Assistant Professor in the Department of Physics at Debre Tabor University, Ethiopia. He previously held the position of Lecturer at the same institution, actively contributing to curriculum development and student mentorship. His leadership experience includes a two-year term as Department Head and three years as Chair of the Ethiopian Space Science Society (Debre Tabor Branch), showcasing his commitment to both academic and community development.

🧪 Research Interests:

Dr. Eyachew Misganew Tegaw is a highly driven researcher with diverse interests spanning medical physics, radiotherapy technologies, medical imaging, radiation dosimetry, nanomedicine, Monte Carlo simulations, and artificial intelligence. His work integrates cutting-edge approaches like deep learning and machine learning with traditional medical physics techniques, aiming to enhance cancer treatment planning and medical imaging. He is especially passionate about nanoparticle-enhanced therapies and computational modeling for improved patient outcomes in oncology.

🔍 Areas for Improvement:

While Dr. Eyachew Misganew Tegaw has made significant strides in academic research, increased visibility through invited talks, expanded international partnerships, and higher engagement in translational clinical projects could further enhance his research impact. Diversifying funding sources and mentoring emerging researchers may also solidify his standing in the global scientific community.

📚 Scientific Contributions

Dr. Eyachew has authored and co-authored numerous peer-reviewed journal articles in high-impact scientific journals. His publications cover a wide range of topics such as Monte Carlo simulations for radiotherapy, nanoparticle-enhanced imaging and treatment, and explainable AI in oncology. Notable among his recent works is a 2025 article in Scientific Reports comparing survival outcomes in breast cancer surgery, and another accepted paper focusing on AI for lung cancer survival prediction. His systematic reviews and meta-analyses have also significantly contributed to evidence-based practice in cancer diagnosis and therapy.

Publications:

  1. Diagnostic performance of mammography and ultrasound in breast cancer: A systematic review and meta-analysis
    Journal of Ultrasound, 2023

  2. Dosimetric characteristics of the INTRABEAM® system with spherical applicators in the presence of air gaps and tissue heterogeneities
    Radiation and Environmental Biophysics, 2020

  3. Techniques for generating attenuation map using cardiac SPECT emission data only: A systematic review
    Annals of Nuclear Medicine, 2019

  4. Molecular imaging approaches in the diagnosis of breast cancer: A systematic review and meta-analysis
    Iranian Journal of Nuclear Medicine, 2020

  5. Comparison of organs at risk doses between deep inspiration breath-hold and free-breathing techniques during radiotherapy of left-sided breast cancer: A meta-analysis
    Polish Journal of Medical Physics and Engineering, 2022

  6. Gold-nanoparticle-enriched breast tissue in breast cancer treatment using the INTRABEAM® system: A Monte Carlo study
    Radiation and Environmental Biophysics, 2022

  7. Dosimetric effect of nanoparticles in the breast cancer treatment using INTRABEAM® system with spherical applicators in the presence of tissue heterogeneities: A Monte Carlo study
    Biomedical Physics & Engineering Express, 2021

  8. A comparison between EGSnrc/Epp and MCNP in simulation of dosimetric parameters for radiotherapy applications
    Journal of Biomedical Physics & Engineering, 2021

  9. Explainable machine learning to compare the overall survival status between patients receiving mastectomy and breast conserving surgeries
    Scientific Reports, 2025

  10. Attenuation correction for dedicated cardiac SPECT imaging without using transmission data
    Molecular Imaging and Radionuclide Therapy, 2023

  11. Comparative study between EPID and CBCT for radiation treatment verifications
    Iranian Journal of Medical Physics, 2018